Product Program year 2020 Source: CMS Open Payments

Relexxii

Drug Adhd

NDC 68025-084-10

Open in the dashboard

General payments

$83,480

5,300 payments

Research payments

$0

0 payments

Through program year 2020, $83,480 in general payments and $0 in research payments were reported against Relexxii (Adhd).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2020 General $13,704 840
2019 General $69,776 4,460

Breakdown

Who paid General payments · program years 2019–2020
  1. Vertical Pharmaceuticals, LLC $83,480 5,300 payments
Top recipients General payments · program year 2020
  1. John Steffek Child & Adolescent Psychiatry · Spring, TX $135 <1% · 9 payments
  2. Emmanuel Sackey Pediatrics · Ennis, TX $65 <1% · 3 payments
  3. Mary Jane Pionk Developmental - Behavioral Pediatrics · San Jose, CA $60 <1% · 3 payments
  4. Richard Breen Pediatrics · Hilliard, OH $53 <1% · 3 payments
  5. Dana Schultz Pediatrics · Hilliard, OH $53 <1% · 3 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2020.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2020
  1. Pediatrics $3,029 23% · 167 practitioners
  2. Psychiatry Psychiatry & Neurology $2,784 21% · 153 practitioners
  3. Neurology Psychiatry & Neurology $2,764 21% · 151 practitioners
  4. Obstetrics & Gynecology $1,383 10% · 91 practitioners
  5. Family Medicine $958 7% · 58 practitioners

The top 5 of 32 specialties; each share is of general payments naming this product to practitioners with a specialty in 2020. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2020
  1. Texas $1,854 14% · 85 recipients
  2. Ohio $1,280 9% · 69 recipients
  3. California $954 7% · 51 recipients
  4. New York $942 7% · 54 recipients
  5. Pennsylvania $889 6% · 48 recipients

The top 5 of 37 states; each share is of general payments naming this product in 2020 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

16

Prescriptions dispensed, refills included

Drug cost

$5,726

Paid at the pharmacy, in all

Prescribers

1

With 11 or more claims of it

Medicare Part D drugs matched to RELEXXII, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Relexxii Methylphenidate Hcl Same name 1 16 $5,726

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

1 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Jackie Stevens Nurse Practitioner MN 16 $5,726 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

5,300 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2020

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record